120 related articles for article (PubMed ID: 12486316)
1. Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis.
Rameshwar P; Oh HS; Yook C; Gascon P; Chang VT
Acta Haematol; 2003; 109(1):1-10. PubMed ID: 12486316
[TBL] [Abstract][Full Text] [Related]
2. Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis.
Rameshwar P; Joshi DD; Yadav P; Qian J; Gascon P; Chang VT; Anjaria D; Harrison JS; Song X
Blood; 2001 May; 97(10):3025-31. PubMed ID: 11342427
[TBL] [Abstract][Full Text] [Related]
3. Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis.
Chang VT; Yook C; Rameshwar P
Leuk Lymphoma; 2013 Mar; 54(3):631-8. PubMed ID: 22906243
[TBL] [Abstract][Full Text] [Related]
4. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
Virchows Arch; 2024 May; 484(5):837-845. PubMed ID: 38602559
[TBL] [Abstract][Full Text] [Related]
5. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
6. Systemic transforming growth factor-beta in patients with bone marrow fibrosis--pathophysiological implications.
Rameshwar P; Chang VT; Thacker UF; Gascón P
Am J Hematol; 1998 Oct; 59(2):133-42. PubMed ID: 9766798
[TBL] [Abstract][Full Text] [Related]
7. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?
Barosi G; Gale RP
Leuk Res; 2011 May; 35(5):563-5. PubMed ID: 21296418
[TBL] [Abstract][Full Text] [Related]
9. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta.
Rameshwar P; Denny TN; Stein D; Gascón P
J Immunol; 1994 Sep; 153(6):2819-30. PubMed ID: 7521370
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
12. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL).
Aziz KA; Till KJ; Chen H; Slupsky JR; Campbell F; Cawley JC; Zuzel M
Blood; 2003 Aug; 102(3):1051-6. PubMed ID: 12689941
[TBL] [Abstract][Full Text] [Related]
13. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.
Shehata M; Schwarzmeier JD; Hilgarth M; Hubmann R; Duechler M; Gisslinger H
J Clin Invest; 2004 Mar; 113(5):676-85. PubMed ID: 14991065
[TBL] [Abstract][Full Text] [Related]
15. Fibrosis and bone marrow: understanding causation and pathobiology.
Ghosh K; Shome DK; Kulkarni B; Ghosh MK; Ghosh K
J Transl Med; 2023 Oct; 21(1):703. PubMed ID: 37814319
[TBL] [Abstract][Full Text] [Related]
16. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC
Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
Nagao T; Yonekura S
Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
[No Abstract] [Full Text] [Related]
18. Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis.
Rameshwar P; Chang VT; Gascón P
Br J Haematol; 1996 Apr; 93(1):22-9. PubMed ID: 8611464
[TBL] [Abstract][Full Text] [Related]
19. Structural similarity between the bone marrow extracellular matrix protein and neurokinin 1 could be the limiting factor in the hematopoietic effects of substance P.
Rameshwar P; Gascon P; Bandari PS; Joshi DD; Fernandes A; Dang A
Can J Physiol Pharmacol; 2002 May; 80(5):475-81. PubMed ID: 12056556
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
